---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-082787"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:08:41.206572+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aardvark Therapeutics pauses Phase 3 HERO trial for ARD-101 in PWS due to cardiac signals

## Summary
- Voluntary pause of Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) for ARD-101 in Prader-Willi Syndrome.
- Decision based on reversible cardiac observations at above-target therapeutic doses in a healthy volunteer study.
- No longer expects topline data in Q3 2026; plans to provide guidance in Q2 2026.
- Company conducting comprehensive data review and collaborating with FDA and clinical experts.

## SEC filing metadata
- accession: 0001193125-26-082787
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/0001193125-26-082787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/ck0001774857-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-082787
- JSON: https://secwatch.observer/filing/0001193125-26-082787.json
- Plain text: https://secwatch.observer/filing/0001193125-26-082787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.